Potassium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Potassium
Accession Number
DB14500
Type
Small Molecule
Groups
Approved, Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • K
  • Kalium
  • Potasio
  • Potassium metal
  • Potassium, elemental
  • Potassium, metal
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
K Lyte Cl PwrPowder, for solution1.86 gOralBristol Labs Division Of Bristol Myers Squibb1965-12-311997-08-14Canada
Polycitra-KSolution398 mgOralJanssen Pharmaceuticals1996-12-312009-10-02Canada
Polycitra-KPowder1.193 gOralAlza1996-12-312001-08-01Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Complexed Potassium Tablets - 99mgTablet99 mgOralAlbion1996-09-062002-07-12Canada
K Lyte Tab Lime & Orange FlavTablet, effervescent975 mgOralBristol Labs Division Of Bristol Myers Squibb1965-12-311997-08-14Canada
Port A Mins Super Potassium 99Tablet99 mgOralGreat Earth Companies, Inc.1998-08-252002-10-02Canada
Potassium 250Capsule250 mgOralSeroyal International Inc.1997-12-122009-07-06Canada
Potassium 99 - CapletTablet99 mgOralHealth Wise Nutrition Inc.1995-12-312002-07-18Canada
Potassium 99mg TabletsTablet99 mgOralBioforce Canada Inc.1994-12-311997-04-14Canada
Potassium Gluconate Tab 550mg USPTablet92 mgOralPharmavite1991-12-312000-08-24Canada
Potassium Gluconate Tablets 99mg USPTablet99 mgOralRoyal Bodycare Canada Inc.1992-12-312001-08-07Canada
Potassium RougierLiquid780 mgOralRougier Pharma Division Of Ratiopharm Inc1965-12-312001-09-05Canada
Potassium Tab 99mgTablet99 mgOralDa Vinci Laboratories, Division Of Foodscience Corporation1981-12-311997-05-08Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
24 Multivitamins + MineralsPotassium (15 mg) + Ascorbic acid (150 mg) + Beta carotene (10000 unit) + Biotin (25 mcg) + Calcium (130 mg) + Cholecalciferol (400 unit) + Choline bitartrate (25 mg) + Chromium (20 mcg) + Copper (1 mg) + Cyanocobalamin (25 mcg) + Ferrous fumarate (15 mg) + Folic acid (.8 mg) + Inositol (25 mg) + Magnesium (65 mg) + Manganese (2 mg) + Molybdenum (20 mcg) + Niacin (25 mg) + Calcium pantothenate (25 mg) + Potassium Iodide (.1 mg) + Pyridoxine hydrochloride (25 mg) + Racemethionine (25 mg) + Riboflavin (25 mg) + Selenium (20 mcg) + Thiamine hydrochloride (25 mg) + Vanadium (20 mcg) + Vitamin A palmitate (5000 unit) + Vitamin E (50 unit) + Zinc (10 mg)TabletOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1997-04-302002-07-31Canada
Advanced B & T FormulaPotassium (16.67 mg) + Ascorbic acid (33.3 mg) + Calcium (200 mg) + Chromium (33.33 mcg) + Copper (0.5 mg) + Cyanocobalamin (6.67 mcg) + Folic acid (0.133 mg) + Iron (1.67 mg) + Magnesium (83.3 mg) + Manganese (3.33 mg) + Nicotinamide (6.67 mg) + Calcium pantothenate (5 mg) + Phosphorus (100 mg) + Pyridoxine hydrochloride (6.67 mg) + Riboflavin (2.67 mg) + Selenium (33.33 mcg) + Silicon (0.333 mg) + Sodium molybdate (16.67 mcg) + Thiamine (2.67 mg) + Vanadium (8.33 mg) + Vitamin D (66.67 unit) + Zinc (5 mg)CapsuleOralNutraceutical CorporationNot applicableNot applicableCanada
Aqua-S SupplementPotassium (20 mg) + Pyridoxine hydrochloride (4 mg)TabletOralGarden State NutritionalsNot applicableNot applicableCanada
B 6 PlusPotassium (50 mg) + Magnesium (50 mg) + Niacin (20 mg) + Pyridoxine (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg)TabletOralAnabolic Laboratories Inc.1967-12-312004-03-15Canada
BseltzerPotassium (330 mg) + Ascorbic acid (60 mg) + Calcium (1000 mg) + Cholecalciferol (400 unit) + Folic acid (0.4 mg) + Magnesium (400 mg) + Zinc (15 mg)Granule, effervescentOralAbundance Marketing Ltd.2001-11-112007-07-23Canada
Buffered Vitamin C Powder With Ca Mg and KPotassium (19.8 mg) + Ascorbic acid (470 mg) + Calcium (70 mg) + Magnesium (70 mg)PowderOralThorne Research Inc.1997-04-182005-06-21Canada
Buffered Vitamin C Pwr W Cal-mag-potassiumPotassium (15 mg) + Ascorbic acid (359.55 mg) + Calcium (68.25 mg) + Magnesium (34.42 mg) + Magnesium (4.21 mg)PowderOralSisu Inc.1987-12-312009-08-04Canada
C-1000 Plus Zinc & PotassiumPotassium (12 mg) + Potassium (13 mg) + Calcium ascorbate (1 g) + Zinc (5 mg)TabletOralNu Life Nutrition Ltd.1987-12-312005-03-15Canada
C-1000 Plus Zinc & PotassiumPotassium (12 mg) + Potassium (13 mg) + Calcium ascorbate (1 g) + Zinc (5 mg)TabletOralNu Life Nutrition Ltd.1987-12-312005-03-15Canada
C. Vit-min FormulaPotassium (40 mg) + Ascorbic acid (100 mg) + Biotin (30 mcg) + Calcium (175 mg) + Cholecalciferol (400 unit) + Choline (30 mg) + Chromium (50 mcg) + Copper (5 mg) + Cyanocobalamin (100 mcg) + Ferrous fumarate (10 mg) + Folic acid (0.600 mg) + Inositol (30 mg) + Magnesium (80 mg) + Manganese (5 mg) + Molybdenum (25 mcg) + Nicotinamide (50 mg) + Calcium pantothenate (50 mg) + Potassium Iodide (0.15 mg) + Pyridoxine hydrochloride (50 mg) + Racemethionine (3 mg) + Riboflavin (50 mg) + Sodium selenite (200 mcg) + Silicon (0.01 mg) + Thiamine (50 mg) + Vanadium (10 mcg) + Vitamin A (5000 unit) + Zinc (40 mg) + alpha-Tocopherol acetate (100 unit)TabletOralNutramed Laboratories Inc.Not applicableNot applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
PurigoPotassium (9.3 g/100mL) + Calcium Carbonate (18 g/100mL) + Silicon dioxide (31 g/100mL)LiquidTopicalSun Jin Yu Ji Co2017-08-01Not applicableUs
Categories
UNII
RWP5GA015D
CAS number
7440-09-7
Weight
Average: 39.0983
Monoisotopic: 38.963706861
Chemical Formula
K
InChI Key
NTTOTNSKUYCDAV-UHFFFAOYSA-N
InChI
InChI=1S/K.H
IUPAC Name
potassium hydride
SMILES
[KH]

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidThe risk or severity of hyperkalemia can be increased when Potassium is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
AbacavirPotassium may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
AcarbosePotassium may increase the excretion rate of Acarbose which could result in a lower serum level and potentially a reduction in efficacy.
AcebutololPotassium may increase the hyperkalemic activities of Acebutolol.
AceclofenacPotassium may increase the hyperkalemic activities of Aceclofenac.
AcemetacinThe therapeutic efficacy of Potassium can be decreased when used in combination with Acemetacin.
AcetaminophenPotassium may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Potassium which could result in a higher serum level.
AclidiniumPotassium may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy.
AcrivastinePotassium may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
16787786
ChEBI
32589
Wikipedia
Potassium
ATC Codes
C03AB03 — Hydrochlorothiazide and potassiumC03BB07 — Clofenamide and potassiumC03BB02 — Quinethazone and potassiumC03BB04 — Chlortalidone and potassiumC03AB01 — Bendroflumethiazide and potassiumC03AB08 — Methyclothiazide and potassiumC03AB04 — Chlorothiazide and potassiumC03BB05 — Mefruside and potassiumC03AB07 — Cyclopenthiazide and potassiumC03BB03 — Clopamide and potassiumC03AB05 — Polythiazide and potassiumC03CB01 — Furosemide and potassiumC03AB09 — Cyclothiazide and potassiumC03AB02 — Hydroflumethiazide and potassiumC03CB02 — Bumetanide and potassiumC03AB06 — Trichlormethiazide and potassium
AHFS Codes
  • 88:29.00* — Minerals
  • 40:12.00 — Replacement Preparations

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral
Granule, effervescentOral
Tablet, extended releaseOral
PowderOral
Powder, for solutionOral1.86 g
Tablet, effervescentOral975 mg
Tablet, effervescentOral
LiquidOral
TabletOral
PowderOral1.193 g
SolutionOral398 mg
CapsuleOral250 mg
TabletOral92 mg
TabletOral99 mg
LiquidOral780 mg
LiquidTopical
Powder, for solutionOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.13ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0.8 m3·mol-1ChemAxon
Polarizability2.44 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Drug created on July 11, 2018 10:37 / Updated on July 18, 2019 19:08